nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—ROS1—malignant glioma	0.187	0.281	CbGaD
Crizotinib—ACVR1—malignant glioma	0.159	0.239	CbGaD
Crizotinib—PTK2—malignant glioma	0.136	0.203	CbGaD
Crizotinib—MET—malignant glioma	0.101	0.151	CbGaD
Crizotinib—NTRK1—malignant glioma	0.0837	0.126	CbGaD
Crizotinib—Disease progression—Carmustine—malignant glioma	0.00388	0.0686	CcSEcCtD
Crizotinib—Disorder sight—Temozolomide—malignant glioma	0.00172	0.0304	CcSEcCtD
Crizotinib—Lymphopenia—Temozolomide—malignant glioma	0.0016	0.0283	CcSEcCtD
Crizotinib—Febrile neutropenia—Carmustine—malignant glioma	0.00141	0.0249	CcSEcCtD
Crizotinib—Transaminases increased—Carmustine—malignant glioma	0.00139	0.0246	CcSEcCtD
Crizotinib—Visual acuity reduced—Temozolomide—malignant glioma	0.00138	0.0243	CcSEcCtD
Crizotinib—Febrile neutropenia—Temozolomide—malignant glioma	0.00136	0.0241	CcSEcCtD
Crizotinib—Burning sensation—Carmustine—malignant glioma	0.00122	0.0216	CcSEcCtD
Crizotinib—Interstitial lung disease—Carmustine—malignant glioma	0.0012	0.0212	CcSEcCtD
Crizotinib—Interstitial lung disease—Temozolomide—malignant glioma	0.00116	0.0205	CcSEcCtD
Crizotinib—Hepatotoxicity—Carmustine—malignant glioma	0.0011	0.0194	CcSEcCtD
Crizotinib—Abscess—Carmustine—malignant glioma	0.00107	0.0189	CcSEcCtD
Crizotinib—Hepatotoxicity—Temozolomide—malignant glioma	0.00106	0.0187	CcSEcCtD
Crizotinib—Gamma-glutamyltransferase increased—Temozolomide—malignant glioma	0.000996	0.0176	CcSEcCtD
Crizotinib—Gait disturbance—Carmustine—malignant glioma	0.000869	0.0153	CcSEcCtD
Crizotinib—Pulmonary embolism—Carmustine—malignant glioma	0.000848	0.015	CcSEcCtD
Crizotinib—Gait disturbance—Temozolomide—malignant glioma	0.00084	0.0148	CcSEcCtD
Crizotinib—Respiratory failure—Temozolomide—malignant glioma	0.000835	0.0147	CcSEcCtD
Crizotinib—Phosphatase alkaline increased—Temozolomide—malignant glioma	0.00082	0.0145	CcSEcCtD
Crizotinib—Pulmonary embolism—Temozolomide—malignant glioma	0.00082	0.0145	CcSEcCtD
Crizotinib—Neuropathy—Carmustine—malignant glioma	0.000796	0.0141	CcSEcCtD
Crizotinib—Neuropathy—Temozolomide—malignant glioma	0.000769	0.0136	CcSEcCtD
Crizotinib—Sepsis—Carmustine—malignant glioma	0.000736	0.013	CcSEcCtD
Crizotinib—Blood alkaline phosphatase increased—Temozolomide—malignant glioma	0.000684	0.0121	CcSEcCtD
Crizotinib—Hepatic failure—Temozolomide—malignant glioma	0.000662	0.0117	CcSEcCtD
Crizotinib—Diplopia—Carmustine—malignant glioma	0.000616	0.0109	CcSEcCtD
Crizotinib—Diplopia—Temozolomide—malignant glioma	0.000595	0.0105	CcSEcCtD
Crizotinib—Face oedema—Carmustine—malignant glioma	0.000594	0.0105	CcSEcCtD
Crizotinib—Face oedema—Temozolomide—malignant glioma	0.000574	0.0101	CcSEcCtD
Crizotinib—Hypokalaemia—Carmustine—malignant glioma	0.00056	0.0099	CcSEcCtD
Crizotinib—Muscular weakness—Carmustine—malignant glioma	0.000543	0.00959	CcSEcCtD
Crizotinib—Hypokalaemia—Temozolomide—malignant glioma	0.000541	0.00956	CcSEcCtD
Crizotinib—Aspartate aminotransferase increased—Temozolomide—malignant glioma	0.000536	0.00946	CcSEcCtD
Crizotinib—Muscular weakness—Temozolomide—malignant glioma	0.000525	0.00927	CcSEcCtD
Crizotinib—Alanine aminotransferase increased—Temozolomide—malignant glioma	0.000525	0.00927	CcSEcCtD
Crizotinib—Neutropenia—Carmustine—malignant glioma	0.000498	0.00879	CcSEcCtD
Crizotinib—Neutropenia—Temozolomide—malignant glioma	0.000481	0.00849	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Temozolomide—malignant glioma	0.000478	0.00844	CcSEcCtD
Crizotinib—Pneumonia—Carmustine—malignant glioma	0.000477	0.00843	CcSEcCtD
Crizotinib—Weight decreased—Temozolomide—malignant glioma	0.000465	0.00822	CcSEcCtD
Crizotinib—Neuropathy peripheral—Carmustine—malignant glioma	0.000465	0.00821	CcSEcCtD
Crizotinib—Pneumonia—Temozolomide—malignant glioma	0.000461	0.00815	CcSEcCtD
Crizotinib—Infestation—Temozolomide—malignant glioma	0.000458	0.0081	CcSEcCtD
Crizotinib—Infestation NOS—Temozolomide—malignant glioma	0.000458	0.0081	CcSEcCtD
Crizotinib—Neuropathy peripheral—Temozolomide—malignant glioma	0.000449	0.00794	CcSEcCtD
Crizotinib—Hepatobiliary disease—Temozolomide—malignant glioma	0.000434	0.00766	CcSEcCtD
Crizotinib—Hypoaesthesia—Carmustine—malignant glioma	0.000424	0.00749	CcSEcCtD
Crizotinib—Oedema peripheral—Carmustine—malignant glioma	0.00042	0.00741	CcSEcCtD
Crizotinib—Visual impairment—Carmustine—malignant glioma	0.00041	0.00725	CcSEcCtD
Crizotinib—Hypoaesthesia—Temozolomide—malignant glioma	0.000409	0.00723	CcSEcCtD
Crizotinib—Urinary tract disorder—Temozolomide—malignant glioma	0.000406	0.00718	CcSEcCtD
Crizotinib—Oedema peripheral—Temozolomide—malignant glioma	0.000405	0.00716	CcSEcCtD
Crizotinib—Urethral disorder—Temozolomide—malignant glioma	0.000403	0.00713	CcSEcCtD
Crizotinib—Eye disorder—Carmustine—malignant glioma	0.000398	0.00703	CcSEcCtD
Crizotinib—Visual impairment—Temozolomide—malignant glioma	0.000397	0.00701	CcSEcCtD
Crizotinib—Eye disorder—Temozolomide—malignant glioma	0.000385	0.00679	CcSEcCtD
Crizotinib—Cardiac disorder—Temozolomide—malignant glioma	0.000382	0.00675	CcSEcCtD
Crizotinib—Arrhythmia—Carmustine—malignant glioma	0.00038	0.00672	CcSEcCtD
Crizotinib—Mediastinal disorder—Temozolomide—malignant glioma	0.000371	0.00655	CcSEcCtD
Crizotinib—Malnutrition—Carmustine—malignant glioma	0.000371	0.00655	CcSEcCtD
Crizotinib—Malnutrition—Temozolomide—malignant glioma	0.000358	0.00633	CcSEcCtD
Crizotinib—Dysgeusia—Temozolomide—malignant glioma	0.000351	0.0062	CcSEcCtD
Crizotinib—Vision blurred—Carmustine—malignant glioma	0.000349	0.00617	CcSEcCtD
Crizotinib—Anaemia—Carmustine—malignant glioma	0.000343	0.00605	CcSEcCtD
Crizotinib—Vision blurred—Temozolomide—malignant glioma	0.000338	0.00596	CcSEcCtD
Crizotinib—Leukopenia—Carmustine—malignant glioma	0.000332	0.00586	CcSEcCtD
Crizotinib—Anaemia—Temozolomide—malignant glioma	0.000331	0.00585	CcSEcCtD
Crizotinib—Leukopenia—Temozolomide—malignant glioma	0.000321	0.00567	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—malignant glioma	0.000303	0.00535	CcSEcCtD
Crizotinib—Oedema—Carmustine—malignant glioma	0.000303	0.00534	CcSEcCtD
Crizotinib—Infection—Carmustine—malignant glioma	0.000301	0.00531	CcSEcCtD
Crizotinib—Oedema—Temozolomide—malignant glioma	0.000292	0.00517	CcSEcCtD
Crizotinib—Infection—Temozolomide—malignant glioma	0.00029	0.00513	CcSEcCtD
Crizotinib—Nervous system disorder—Temozolomide—malignant glioma	0.000287	0.00507	CcSEcCtD
Crizotinib—Skin disorder—Temozolomide—malignant glioma	0.000284	0.00502	CcSEcCtD
Crizotinib—Paraesthesia—Carmustine—malignant glioma	0.000272	0.0048	CcSEcCtD
Crizotinib—TAOK2—cerebellum—malignant glioma	0.00027	0.00282	CbGeAlD
Crizotinib—Dyspnoea—Carmustine—malignant glioma	0.00027	0.00477	CcSEcCtD
Crizotinib—EPHB4—telencephalon—malignant glioma	0.000269	0.00281	CbGeAlD
Crizotinib—TESK1—midbrain—malignant glioma	0.000269	0.00281	CbGeAlD
Crizotinib—JAK2—telencephalon—malignant glioma	0.000267	0.00279	CbGeAlD
Crizotinib—EPHA3—central nervous system—malignant glioma	0.000266	0.00278	CbGeAlD
Crizotinib—ACVR1B—central nervous system—malignant glioma	0.000266	0.00278	CbGeAlD
Crizotinib—TAOK3—brainstem—malignant glioma	0.000265	0.00276	CbGeAlD
Crizotinib—PRKD3—brain—malignant glioma	0.000264	0.00276	CbGeAlD
Crizotinib—Decreased appetite—Carmustine—malignant glioma	0.000263	0.00465	CcSEcCtD
Crizotinib—Paraesthesia—Temozolomide—malignant glioma	0.000263	0.00464	CcSEcCtD
Crizotinib—TESK1—spinal cord—malignant glioma	0.000262	0.00274	CbGeAlD
Crizotinib—Gastrointestinal disorder—Carmustine—malignant glioma	0.000261	0.00461	CcSEcCtD
Crizotinib—Dyspnoea—Temozolomide—malignant glioma	0.000261	0.0046	CcSEcCtD
Crizotinib—ACVR1B—cerebellum—malignant glioma	0.00026	0.00272	CbGeAlD
Crizotinib—Constipation—Carmustine—malignant glioma	0.000259	0.00457	CcSEcCtD
Crizotinib—YES1—retina—malignant glioma	0.000259	0.0027	CbGeAlD
Crizotinib—DSTYK—brain—malignant glioma	0.000258	0.0027	CbGeAlD
Crizotinib—TEK—telencephalon—malignant glioma	0.000258	0.00269	CbGeAlD
Crizotinib—MAP4K5—telencephalon—malignant glioma	0.000258	0.00269	CbGeAlD
Crizotinib—Dyspepsia—Temozolomide—malignant glioma	0.000257	0.00455	CcSEcCtD
Crizotinib—TAOK3—retina—malignant glioma	0.000255	0.00267	CbGeAlD
Crizotinib—Decreased appetite—Temozolomide—malignant glioma	0.000254	0.00449	CcSEcCtD
Crizotinib—JAK3—central nervous system—malignant glioma	0.000254	0.00265	CbGeAlD
Crizotinib—EPHA6—central nervous system—malignant glioma	0.000254	0.00265	CbGeAlD
Crizotinib—ACVR1—midbrain—malignant glioma	0.000253	0.00264	CbGeAlD
Crizotinib—MAP3K12—midbrain—malignant glioma	0.000253	0.00264	CbGeAlD
Crizotinib—CSF1R—embryo—malignant glioma	0.000253	0.00264	CbGeAlD
Crizotinib—DCLK1—central nervous system—malignant glioma	0.000252	0.00264	CbGeAlD
Crizotinib—Gastrointestinal disorder—Temozolomide—malignant glioma	0.000252	0.00446	CcSEcCtD
Crizotinib—CASK—brain—malignant glioma	0.000252	0.00263	CbGeAlD
Crizotinib—LTK—brain—malignant glioma	0.000252	0.00263	CbGeAlD
Crizotinib—Fatigue—Temozolomide—malignant glioma	0.000252	0.00445	CcSEcCtD
Crizotinib—RIPK2—medulla oblongata—malignant glioma	0.00025	0.00261	CbGeAlD
Crizotinib—Constipation—Temozolomide—malignant glioma	0.00025	0.00442	CcSEcCtD
Crizotinib—LIMK2—spinal cord—malignant glioma	0.00025	0.00261	CbGeAlD
Crizotinib—STK4—central nervous system—malignant glioma	0.000249	0.0026	CbGeAlD
Crizotinib—SRC—retina—malignant glioma	0.000249	0.0026	CbGeAlD
Crizotinib—JAK3—cerebellum—malignant glioma	0.000248	0.00259	CbGeAlD
Crizotinib—STK35—midbrain—malignant glioma	0.000248	0.00259	CbGeAlD
Crizotinib—MAP3K12—spinal cord—malignant glioma	0.000247	0.00258	CbGeAlD
Crizotinib—ACVR1—spinal cord—malignant glioma	0.000247	0.00258	CbGeAlD
Crizotinib—DCLK1—cerebellum—malignant glioma	0.000247	0.00258	CbGeAlD
Crizotinib—EPHB6—telencephalon—malignant glioma	0.000246	0.00257	CbGeAlD
Crizotinib—MAPK7—brain—malignant glioma	0.000244	0.00255	CbGeAlD
Crizotinib—STK4—cerebellum—malignant glioma	0.000244	0.00255	CbGeAlD
Crizotinib—EPHA4—medulla oblongata—malignant glioma	0.000242	0.00253	CbGeAlD
Crizotinib—EPHA8—brain—malignant glioma	0.000242	0.00253	CbGeAlD
Crizotinib—FES—brain—malignant glioma	0.000242	0.00253	CbGeAlD
Crizotinib—Body temperature increased—Carmustine—malignant glioma	0.000239	0.00423	CcSEcCtD
Crizotinib—BMP2K—midbrain—malignant glioma	0.000239	0.00249	CbGeAlD
Crizotinib—YES1—telencephalon—malignant glioma	0.000238	0.00248	CbGeAlD
Crizotinib—ALK—central nervous system—malignant glioma	0.000236	0.00246	CbGeAlD
Crizotinib—TYRO3—central nervous system—malignant glioma	0.000236	0.00246	CbGeAlD
Crizotinib—FER—central nervous system—malignant glioma	0.000236	0.00246	CbGeAlD
Crizotinib—EPHA5—central nervous system—malignant glioma	0.000236	0.00246	CbGeAlD
Crizotinib—TAOK3—telencephalon—malignant glioma	0.000235	0.00245	CbGeAlD
Crizotinib—LYN—central nervous system—malignant glioma	0.000234	0.00245	CbGeAlD
Crizotinib—BMP2K—spinal cord—malignant glioma	0.000233	0.00243	CbGeAlD
Crizotinib—TBK1—medulla oblongata—malignant glioma	0.000232	0.00243	CbGeAlD
Crizotinib—Body temperature increased—Temozolomide—malignant glioma	0.000231	0.00408	CcSEcCtD
Crizotinib—BMPR1B—central nervous system—malignant glioma	0.000231	0.00241	CbGeAlD
Crizotinib—MAP3K19—central nervous system—malignant glioma	0.000231	0.00241	CbGeAlD
Crizotinib—TYK2—medulla oblongata—malignant glioma	0.000231	0.00241	CbGeAlD
Crizotinib—EPHA5—cerebellum—malignant glioma	0.00023	0.00241	CbGeAlD
Crizotinib—FER—cerebellum—malignant glioma	0.00023	0.00241	CbGeAlD
Crizotinib—TYRO3—cerebellum—malignant glioma	0.00023	0.00241	CbGeAlD
Crizotinib—SRC—telencephalon—malignant glioma	0.000229	0.00239	CbGeAlD
Crizotinib—MET—brain—malignant glioma	0.000229	0.00239	CbGeAlD
Crizotinib—RIPK2—midbrain—malignant glioma	0.000229	0.00239	CbGeAlD
Crizotinib—TNK1—cerebellum—malignant glioma	0.000228	0.00238	CbGeAlD
Crizotinib—TNK2—central nervous system—malignant glioma	0.000226	0.00236	CbGeAlD
Crizotinib—IGF1R—central nervous system—malignant glioma	0.000226	0.00236	CbGeAlD
Crizotinib—BMPR1B—cerebellum—malignant glioma	0.000226	0.00236	CbGeAlD
Crizotinib—RPS6KB1—medulla oblongata—malignant glioma	0.000224	0.00233	CbGeAlD
Crizotinib—RIPK2—spinal cord—malignant glioma	0.000223	0.00233	CbGeAlD
Crizotinib—TNK2—cerebellum—malignant glioma	0.000221	0.00231	CbGeAlD
Crizotinib—IGF1R—cerebellum—malignant glioma	0.000221	0.00231	CbGeAlD
Crizotinib—AXL—medulla oblongata—malignant glioma	0.000221	0.00231	CbGeAlD
Crizotinib—CDK7—brain—malignant glioma	0.000221	0.00231	CbGeAlD
Crizotinib—TIE1—central nervous system—malignant glioma	0.00022	0.0023	CbGeAlD
Crizotinib—TAOK2—brain—malignant glioma	0.000219	0.00229	CbGeAlD
Crizotinib—MAP4K2—cerebellum—malignant glioma	0.000218	0.00228	CbGeAlD
Crizotinib—Asthenia—Carmustine—malignant glioma	0.000217	0.00383	CcSEcCtD
Crizotinib—TIE1—cerebellum—malignant glioma	0.000215	0.00225	CbGeAlD
Crizotinib—STK3—cerebellum—malignant glioma	0.000215	0.00225	CbGeAlD
Crizotinib—AURKA—central nervous system—malignant glioma	0.000215	0.00224	CbGeAlD
Crizotinib—SLK—medulla oblongata—malignant glioma	0.000213	0.00222	CbGeAlD
Crizotinib—TESK1—central nervous system—malignant glioma	0.000213	0.00222	CbGeAlD
Crizotinib—TBK1—midbrain—malignant glioma	0.000212	0.00222	CbGeAlD
Crizotinib—PTK2—midbrain—malignant glioma	0.000212	0.00222	CbGeAlD
Crizotinib—EPHB4—medulla oblongata—malignant glioma	0.000211	0.00221	CbGeAlD
Crizotinib—EPHA3—brain—malignant glioma	0.000211	0.00221	CbGeAlD
Crizotinib—ACVR1B—brain—malignant glioma	0.000211	0.00221	CbGeAlD
Crizotinib—TYK2—midbrain—malignant glioma	0.000211	0.0022	CbGeAlD
Crizotinib—JAK2—medulla oblongata—malignant glioma	0.00021	0.00219	CbGeAlD
Crizotinib—Asthenia—Temozolomide—malignant glioma	0.00021	0.00371	CcSEcCtD
Crizotinib—IRAK1—midbrain—malignant glioma	0.000208	0.00217	CbGeAlD
Crizotinib—TESK1—cerebellum—malignant glioma	0.000208	0.00217	CbGeAlD
Crizotinib—PTK2—spinal cord—malignant glioma	0.000207	0.00216	CbGeAlD
Crizotinib—TBK1—spinal cord—malignant glioma	0.000207	0.00216	CbGeAlD
Crizotinib—MERTK—central nervous system—malignant glioma	0.000207	0.00216	CbGeAlD
Crizotinib—Diarrhoea—Carmustine—malignant glioma	0.000207	0.00366	CcSEcCtD
Crizotinib—TYK2—spinal cord—malignant glioma	0.000206	0.00215	CbGeAlD
Crizotinib—CSF1R—telencephalon—malignant glioma	0.000205	0.00215	CbGeAlD
Crizotinib—RPS6KB1—midbrain—malignant glioma	0.000204	0.00213	CbGeAlD
Crizotinib—LIMK2—central nervous system—malignant glioma	0.000203	0.00212	CbGeAlD
Crizotinib—MERTK—cerebellum—malignant glioma	0.000202	0.00211	CbGeAlD
Crizotinib—MAP3K3—medulla oblongata—malignant glioma	0.000202	0.00211	CbGeAlD
Crizotinib—MAP4K5—medulla oblongata—malignant glioma	0.000202	0.00211	CbGeAlD
Crizotinib—TEK—medulla oblongata—malignant glioma	0.000202	0.00211	CbGeAlD
Crizotinib—AXL—midbrain—malignant glioma	0.000202	0.00211	CbGeAlD
Crizotinib—EPHA6—brain—malignant glioma	0.000202	0.00211	CbGeAlD
Crizotinib—JAK3—brain—malignant glioma	0.000202	0.00211	CbGeAlD
Crizotinib—DCLK1—brain—malignant glioma	0.0002	0.00209	CbGeAlD
Crizotinib—ACVR1—central nervous system—malignant glioma	0.0002	0.00209	CbGeAlD
Crizotinib—MAP3K12—central nervous system—malignant glioma	0.0002	0.00209	CbGeAlD
Crizotinib—Dizziness—Carmustine—malignant glioma	0.0002	0.00353	CcSEcCtD
Crizotinib—Diarrhoea—Temozolomide—malignant glioma	0.0002	0.00353	CcSEcCtD
Crizotinib—ABL1—embryo—malignant glioma	0.0002	0.00209	CbGeAlD
Crizotinib—RPS6KB1—spinal cord—malignant glioma	0.000199	0.00208	CbGeAlD
Crizotinib—PLK4—brain—malignant glioma	0.000199	0.00208	CbGeAlD
Crizotinib—STK4—brain—malignant glioma	0.000198	0.00207	CbGeAlD
Crizotinib—LIMK2—cerebellum—malignant glioma	0.000198	0.00207	CbGeAlD
Crizotinib—AXL—spinal cord—malignant glioma	0.000197	0.00206	CbGeAlD
Crizotinib—NUAK2—cerebellum—malignant glioma	0.000197	0.00206	CbGeAlD
Crizotinib—STK35—central nervous system—malignant glioma	0.000196	0.00205	CbGeAlD
Crizotinib—FLT3—cerebellum—malignant glioma	0.000196	0.00205	CbGeAlD
Crizotinib—MAP3K12—cerebellum—malignant glioma	0.000196	0.00205	CbGeAlD
Crizotinib—ACVR1—cerebellum—malignant glioma	0.000196	0.00205	CbGeAlD
Crizotinib—SLK—midbrain—malignant glioma	0.000195	0.00203	CbGeAlD
Crizotinib—EPHB6—medulla oblongata—malignant glioma	0.000193	0.00202	CbGeAlD
Crizotinib—Dizziness—Temozolomide—malignant glioma	0.000193	0.00342	CcSEcCtD
Crizotinib—EPHB4—midbrain—malignant glioma	0.000193	0.00202	CbGeAlD
Crizotinib—Vomiting—Carmustine—malignant glioma	0.000192	0.0034	CcSEcCtD
Crizotinib—STK35—cerebellum—malignant glioma	0.000192	0.002	CbGeAlD
Crizotinib—Rash—Carmustine—malignant glioma	0.000191	0.00337	CcSEcCtD
Crizotinib—Dermatitis—Carmustine—malignant glioma	0.000191	0.00337	CcSEcCtD
Crizotinib—SLK—spinal cord—malignant glioma	0.00019	0.00198	CbGeAlD
Crizotinib—BMP2K—central nervous system—malignant glioma	0.000189	0.00197	CbGeAlD
Crizotinib—EPHB4—spinal cord—malignant glioma	0.000189	0.00197	CbGeAlD
Crizotinib—JAK2—spinal cord—malignant glioma	0.000187	0.00196	CbGeAlD
Crizotinib—ALK—brain—malignant glioma	0.000187	0.00195	CbGeAlD
Crizotinib—EPHA5—brain—malignant glioma	0.000187	0.00195	CbGeAlD
Crizotinib—TYRO3—brain—malignant glioma	0.000187	0.00195	CbGeAlD
Crizotinib—FER—brain—malignant glioma	0.000187	0.00195	CbGeAlD
Crizotinib—ABL2—cerebellum—malignant glioma	0.000187	0.00195	CbGeAlD
Crizotinib—YES1—medulla oblongata—malignant glioma	0.000187	0.00195	CbGeAlD
Crizotinib—LYN—brain—malignant glioma	0.000186	0.00194	CbGeAlD
Crizotinib—Vomiting—Temozolomide—malignant glioma	0.000186	0.00328	CcSEcCtD
Crizotinib—TNK1—brain—malignant glioma	0.000185	0.00193	CbGeAlD
Crizotinib—MAP4K5—midbrain—malignant glioma	0.000185	0.00193	CbGeAlD
Crizotinib—TEK—midbrain—malignant glioma	0.000185	0.00193	CbGeAlD
Crizotinib—MAP3K3—midbrain—malignant glioma	0.000185	0.00193	CbGeAlD
Crizotinib—BMP2K—cerebellum—malignant glioma	0.000185	0.00193	CbGeAlD
Crizotinib—TAOK3—medulla oblongata—malignant glioma	0.000184	0.00193	CbGeAlD
Crizotinib—Rash—Temozolomide—malignant glioma	0.000184	0.00326	CcSEcCtD
Crizotinib—Dermatitis—Temozolomide—malignant glioma	0.000184	0.00325	CcSEcCtD
Crizotinib—BMPR1B—brain—malignant glioma	0.000183	0.00191	CbGeAlD
Crizotinib—MAP3K19—brain—malignant glioma	0.000183	0.00191	CbGeAlD
Crizotinib—MAP4K1—brain—malignant glioma	0.000183	0.00191	CbGeAlD
Crizotinib—ABL1—brainstem—malignant glioma	0.000183	0.00191	CbGeAlD
Crizotinib—PTK2B—central nervous system—malignant glioma	0.000183	0.00191	CbGeAlD
Crizotinib—TEK—spinal cord—malignant glioma	0.00018	0.00188	CbGeAlD
Crizotinib—MAP4K5—spinal cord—malignant glioma	0.00018	0.00188	CbGeAlD
Crizotinib—MAP3K3—spinal cord—malignant glioma	0.00018	0.00188	CbGeAlD
Crizotinib—TNK2—brain—malignant glioma	0.00018	0.00188	CbGeAlD
Crizotinib—IGF1R—brain—malignant glioma	0.00018	0.00188	CbGeAlD
Crizotinib—Nausea—Carmustine—malignant glioma	0.00018	0.00317	CcSEcCtD
Crizotinib—PTK2B—cerebellum—malignant glioma	0.000178	0.00186	CbGeAlD
Crizotinib—MAP4K2—brain—malignant glioma	0.000177	0.00185	CbGeAlD
Crizotinib—RIPK2—cerebellum—malignant glioma	0.000177	0.00185	CbGeAlD
Crizotinib—EPHB6—midbrain—malignant glioma	0.000177	0.00185	CbGeAlD
Crizotinib—ABL1—retina—malignant glioma	0.000177	0.00184	CbGeAlD
Crizotinib—EPHA4—central nervous system—malignant glioma	0.000175	0.00183	CbGeAlD
Crizotinib—TIE1—brain—malignant glioma	0.000175	0.00183	CbGeAlD
Crizotinib—STK3—brain—malignant glioma	0.000175	0.00183	CbGeAlD
Crizotinib—Nausea—Temozolomide—malignant glioma	0.000174	0.00307	CcSEcCtD
Crizotinib—EPHB6—spinal cord—malignant glioma	0.000172	0.0018	CbGeAlD
Crizotinib—MAP3K2—central nervous system—malignant glioma	0.000172	0.00179	CbGeAlD
Crizotinib—EPHA4—cerebellum—malignant glioma	0.000171	0.00179	CbGeAlD
Crizotinib—YES1—midbrain—malignant glioma	0.000171	0.00178	CbGeAlD
Crizotinib—AURKA—brain—malignant glioma	0.00017	0.00178	CbGeAlD
Crizotinib—TESK1—brain—malignant glioma	0.000169	0.00177	CbGeAlD
Crizotinib—TAOK3—midbrain—malignant glioma	0.000169	0.00176	CbGeAlD
Crizotinib—PTK2—central nervous system—malignant glioma	0.000168	0.00176	CbGeAlD
Crizotinib—TBK1—central nervous system—malignant glioma	0.000168	0.00176	CbGeAlD
Crizotinib—MAP3K2—cerebellum—malignant glioma	0.000168	0.00175	CbGeAlD
Crizotinib—TYK2—central nervous system—malignant glioma	0.000167	0.00174	CbGeAlD
Crizotinib—YES1—spinal cord—malignant glioma	0.000167	0.00174	CbGeAlD
Crizotinib—TAOK3—spinal cord—malignant glioma	0.000165	0.00172	CbGeAlD
Crizotinib—MERTK—brain—malignant glioma	0.000164	0.00172	CbGeAlD
Crizotinib—TBK1—cerebellum—malignant glioma	0.000164	0.00172	CbGeAlD
Crizotinib—PTK2—cerebellum—malignant glioma	0.000164	0.00172	CbGeAlD
Crizotinib—TYK2—cerebellum—malignant glioma	0.000163	0.0017	CbGeAlD
Crizotinib—ABL1—telencephalon—malignant glioma	0.000162	0.0017	CbGeAlD
Crizotinib—RPS6KB1—central nervous system—malignant glioma	0.000162	0.00169	CbGeAlD
Crizotinib—CSF1R—medulla oblongata—malignant glioma	0.000161	0.00169	CbGeAlD
Crizotinib—IRAK1—cerebellum—malignant glioma	0.000161	0.00168	CbGeAlD
Crizotinib—LIMK2—brain—malignant glioma	0.000161	0.00168	CbGeAlD
Crizotinib—FGR—central nervous system—malignant glioma	0.000161	0.00168	CbGeAlD
Crizotinib—SRC—spinal cord—malignant glioma	0.00016	0.00167	CbGeAlD
Crizotinib—NUAK2—brain—malignant glioma	0.00016	0.00167	CbGeAlD
Crizotinib—AXL—central nervous system—malignant glioma	0.00016	0.00167	CbGeAlD
Crizotinib—MAP3K12—brain—malignant glioma	0.000159	0.00166	CbGeAlD
Crizotinib—ACVR1—brain—malignant glioma	0.000159	0.00166	CbGeAlD
Crizotinib—RPS6KB1—cerebellum—malignant glioma	0.000158	0.00165	CbGeAlD
Crizotinib—AXL—cerebellum—malignant glioma	0.000156	0.00163	CbGeAlD
Crizotinib—STK35—brain—malignant glioma	0.000156	0.00163	CbGeAlD
Crizotinib—ABL2—brain—malignant glioma	0.000152	0.00159	CbGeAlD
Crizotinib—JAK2—central nervous system—malignant glioma	0.000152	0.00159	CbGeAlD
Crizotinib—SLK—cerebellum—malignant glioma	0.000151	0.00157	CbGeAlD
Crizotinib—EPHA2—central nervous system—malignant glioma	0.00015	0.00157	CbGeAlD
Crizotinib—BMP2K—brain—malignant glioma	0.00015	0.00157	CbGeAlD
Crizotinib—EPHB4—cerebellum—malignant glioma	0.00015	0.00156	CbGeAlD
Crizotinib—JAK2—cerebellum—malignant glioma	0.000148	0.00155	CbGeAlD
Crizotinib—CSF1R—midbrain—malignant glioma	0.000148	0.00154	CbGeAlD
Crizotinib—MAP4K5—central nervous system—malignant glioma	0.000146	0.00153	CbGeAlD
Crizotinib—TEK—central nervous system—malignant glioma	0.000146	0.00153	CbGeAlD
Crizotinib—MAP3K3—central nervous system—malignant glioma	0.000146	0.00153	CbGeAlD
Crizotinib—PTK2B—brain—malignant glioma	0.000145	0.00151	CbGeAlD
Crizotinib—CSF1R—spinal cord—malignant glioma	0.000144	0.0015	CbGeAlD
Crizotinib—RIPK2—brain—malignant glioma	0.000144	0.0015	CbGeAlD
Crizotinib—MAP4K5—cerebellum—malignant glioma	0.000143	0.00149	CbGeAlD
Crizotinib—TEK—cerebellum—malignant glioma	0.000143	0.00149	CbGeAlD
Crizotinib—MAP3K3—cerebellum—malignant glioma	0.000143	0.00149	CbGeAlD
Crizotinib—EPHB6—central nervous system—malignant glioma	0.00014	0.00146	CbGeAlD
Crizotinib—EPHA4—brain—malignant glioma	0.000139	0.00145	CbGeAlD
Crizotinib—EPHB6—cerebellum—malignant glioma	0.000137	0.00143	CbGeAlD
Crizotinib—MAP3K2—brain—malignant glioma	0.000136	0.00142	CbGeAlD
Crizotinib—YES1—central nervous system—malignant glioma	0.000135	0.00141	CbGeAlD
Crizotinib—STK10—central nervous system—malignant glioma	0.000134	0.0014	CbGeAlD
Crizotinib—TAOK3—central nervous system—malignant glioma	0.000133	0.00139	CbGeAlD
Crizotinib—PTK2—brain—malignant glioma	0.000133	0.00139	CbGeAlD
Crizotinib—TBK1—brain—malignant glioma	0.000133	0.00139	CbGeAlD
Crizotinib—TYK2—brain—malignant glioma	0.000133	0.00138	CbGeAlD
Crizotinib—YES1—cerebellum—malignant glioma	0.000132	0.00138	CbGeAlD
Crizotinib—STK10—cerebellum—malignant glioma	0.000131	0.00137	CbGeAlD
Crizotinib—IRAK1—brain—malignant glioma	0.000131	0.00137	CbGeAlD
Crizotinib—TAOK3—cerebellum—malignant glioma	0.00013	0.00136	CbGeAlD
Crizotinib—SRC—central nervous system—malignant glioma	0.00013	0.00136	CbGeAlD
Crizotinib—RPS6KB1—brain—malignant glioma	0.000128	0.00134	CbGeAlD
Crizotinib—ABL1—medulla oblongata—malignant glioma	0.000128	0.00133	CbGeAlD
Crizotinib—FGR—brain—malignant glioma	0.000128	0.00133	CbGeAlD
Crizotinib—SRC—cerebellum—malignant glioma	0.000127	0.00133	CbGeAlD
Crizotinib—AXL—brain—malignant glioma	0.000127	0.00133	CbGeAlD
Crizotinib—SLK—brain—malignant glioma	0.000122	0.00128	CbGeAlD
Crizotinib—EPHB4—brain—malignant glioma	0.000121	0.00127	CbGeAlD
Crizotinib—JAK2—brain—malignant glioma	0.000121	0.00126	CbGeAlD
Crizotinib—EPHA2—brain—malignant glioma	0.000119	0.00124	CbGeAlD
Crizotinib—CSF1R—central nervous system—malignant glioma	0.000117	0.00122	CbGeAlD
Crizotinib—ABL1—midbrain—malignant glioma	0.000117	0.00122	CbGeAlD
Crizotinib—MAP3K3—brain—malignant glioma	0.000116	0.00121	CbGeAlD
Crizotinib—MAP4K5—brain—malignant glioma	0.000116	0.00121	CbGeAlD
Crizotinib—TEK—brain—malignant glioma	0.000116	0.00121	CbGeAlD
Crizotinib—CSF1R—cerebellum—malignant glioma	0.000114	0.00119	CbGeAlD
Crizotinib—ABL1—spinal cord—malignant glioma	0.000114	0.00119	CbGeAlD
Crizotinib—EPHB6—brain—malignant glioma	0.000111	0.00116	CbGeAlD
Crizotinib—YES1—brain—malignant glioma	0.000107	0.00112	CbGeAlD
Crizotinib—STK10—brain—malignant glioma	0.000106	0.00111	CbGeAlD
Crizotinib—TAOK3—brain—malignant glioma	0.000106	0.00111	CbGeAlD
Crizotinib—ABCB1—blood vessel—malignant glioma	0.000104	0.00109	CbGeAlD
Crizotinib—SRC—brain—malignant glioma	0.000103	0.00108	CbGeAlD
Crizotinib—CSF1R—brain—malignant glioma	9.27e-05	0.000968	CbGeAlD
Crizotinib—ABL1—central nervous system—malignant glioma	9.23e-05	0.000964	CbGeAlD
Crizotinib—ABL1—cerebellum—malignant glioma	9.02e-05	0.000942	CbGeAlD
Crizotinib—ABL1—brain—malignant glioma	7.33e-05	0.000765	CbGeAlD
Crizotinib—ABCB1—embryo—malignant glioma	6.21e-05	0.000648	CbGeAlD
Crizotinib—ABCB1—retina—malignant glioma	5.49e-05	0.000573	CbGeAlD
Crizotinib—ABCB1—telencephalon—malignant glioma	5.05e-05	0.000527	CbGeAlD
Crizotinib—CYP3A4—central nervous system—malignant glioma	4.05e-05	0.000423	CbGeAlD
Crizotinib—ABCB1—medulla oblongata—malignant glioma	3.97e-05	0.000414	CbGeAlD
Crizotinib—ABCB1—midbrain—malignant glioma	3.63e-05	0.000379	CbGeAlD
Crizotinib—ABCB1—spinal cord—malignant glioma	3.54e-05	0.000369	CbGeAlD
Crizotinib—ABCB1—central nervous system—malignant glioma	2.87e-05	0.0003	CbGeAlD
Crizotinib—ABCB1—cerebellum—malignant glioma	2.81e-05	0.000293	CbGeAlD
Crizotinib—ABCB1—brain—malignant glioma	2.28e-05	0.000238	CbGeAlD
Crizotinib—SRC—Developmental Biology—AKT1—malignant glioma	7.47e-07	4.12e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—EGFR—malignant glioma	7.46e-07	4.12e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—KRAS—malignant glioma	7.45e-07	4.12e-06	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—AKT1—malignant glioma	7.45e-07	4.11e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—EGFR—malignant glioma	7.43e-07	4.1e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CYP2C18—malignant glioma	7.42e-07	4.1e-06	CbGpPWpGaD
Crizotinib—TYK2—Disease—PIK3CA—malignant glioma	7.39e-07	4.08e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—HIF1A—malignant glioma	7.39e-07	4.08e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—PIK3CD—malignant glioma	7.38e-07	4.08e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—MMP9—malignant glioma	7.37e-07	4.07e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CD80—malignant glioma	7.36e-07	4.07e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—APC—malignant glioma	7.35e-07	4.06e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—PIK3CG—malignant glioma	7.35e-07	4.06e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—PTEN—malignant glioma	7.33e-07	4.05e-06	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—AKT1—malignant glioma	7.32e-07	4.05e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—MDM2—malignant glioma	7.32e-07	4.04e-06	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—PIK3CA—malignant glioma	7.31e-07	4.04e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—VEGFA—malignant glioma	7.29e-07	4.03e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—RAF1—malignant glioma	7.29e-07	4.03e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—EGF—malignant glioma	7.27e-07	4.01e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—PIK3CA—malignant glioma	7.26e-07	4.01e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—KRAS—malignant glioma	7.23e-07	3.99e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—KRAS—malignant glioma	7.22e-07	3.99e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—STAT3—malignant glioma	7.22e-07	3.99e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—PTPN11—malignant glioma	7.22e-07	3.99e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—ERBB2—malignant glioma	7.21e-07	3.99e-06	CbGpPWpGaD
Crizotinib—PTK2—Immune System—AKT1—malignant glioma	7.2e-07	3.98e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—VEGFA—malignant glioma	7.19e-07	3.97e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—PIK3CA—malignant glioma	7.15e-07	3.95e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—AKT1—malignant glioma	7.15e-07	3.95e-06	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—AKT1—malignant glioma	7.15e-07	3.95e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CAV1—malignant glioma	7.14e-07	3.95e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—STAT3—malignant glioma	7.12e-07	3.93e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—PIK3CB—malignant glioma	7.12e-07	3.93e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—IL1B—malignant glioma	7.11e-07	3.93e-06	CbGpPWpGaD
Crizotinib—YES1—Immune System—AKT1—malignant glioma	7.1e-07	3.92e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—STAT3—malignant glioma	7.1e-07	3.92e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—IL2—malignant glioma	7.08e-07	3.91e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—KDR—malignant glioma	7.06e-07	3.9e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—FGF2—malignant glioma	7.06e-07	3.9e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MDM2—malignant glioma	7.06e-07	3.9e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—PTGS2—malignant glioma	7.05e-07	3.9e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—KRAS—malignant glioma	7.05e-07	3.9e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—RAF1—malignant glioma	7.04e-07	3.89e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—TP53—malignant glioma	7.02e-07	3.88e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—KRAS—malignant glioma	7.02e-07	3.88e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—EGFR—malignant glioma	6.99e-07	3.86e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—ERBB2—malignant glioma	6.96e-07	3.85e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—PTEN—malignant glioma	6.95e-07	3.84e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—TP53—malignant glioma	6.92e-07	3.82e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—BRAF—malignant glioma	6.91e-07	3.82e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—PIK3CB—malignant glioma	6.87e-07	3.8e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—PIK3CA—malignant glioma	6.85e-07	3.78e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—VEGFA—malignant glioma	6.82e-07	3.77e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—F2—malignant glioma	6.8e-07	3.76e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—FN1—malignant glioma	6.8e-07	3.76e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—STAT3—malignant glioma	6.75e-07	3.73e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—GSTP1—malignant glioma	6.75e-07	3.73e-06	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—AKT1—malignant glioma	6.73e-07	3.72e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—STAT3—malignant glioma	6.73e-07	3.72e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—AKT2—malignant glioma	6.72e-07	3.71e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—BAD—malignant glioma	6.72e-07	3.71e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—MYC—malignant glioma	6.71e-07	3.71e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—CAV1—malignant glioma	6.7e-07	3.7e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—PTEN—malignant glioma	6.66e-07	3.68e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—NOTCH1—malignant glioma	6.65e-07	3.68e-06	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—AKT1—malignant glioma	6.65e-07	3.68e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—PIK3CA—malignant glioma	6.64e-07	3.67e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—PIK3CA—malignant glioma	6.64e-07	3.67e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—TP53—malignant glioma	6.62e-07	3.66e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—VEGFA—malignant glioma	6.62e-07	3.66e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—MYC—malignant glioma	6.62e-07	3.66e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MDM2—malignant glioma	6.61e-07	3.65e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CXCL8—malignant glioma	6.6e-07	3.65e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—KRAS—malignant glioma	6.6e-07	3.65e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—MYC—malignant glioma	6.59e-07	3.64e-06	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—AKT1—malignant glioma	6.59e-07	3.64e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—RAF1—malignant glioma	6.59e-07	3.64e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—CAT—malignant glioma	6.57e-07	3.63e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—EGFR—malignant glioma	6.56e-07	3.63e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—STAT3—malignant glioma	6.56e-07	3.62e-06	CbGpPWpGaD
Crizotinib—TYK2—Immune System—AKT1—malignant glioma	6.54e-07	3.61e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CD80—malignant glioma	6.52e-07	3.6e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—ERBB2—malignant glioma	6.52e-07	3.6e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—APC—malignant glioma	6.51e-07	3.59e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PIK3CG—malignant glioma	6.51e-07	3.59e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—PIK3CA—malignant glioma	6.48e-07	3.58e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—EGFR—malignant glioma	6.47e-07	3.58e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—PIK3CD—malignant glioma	6.46e-07	3.57e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—EGFR—malignant glioma	6.45e-07	3.56e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—PIK3CA—malignant glioma	6.45e-07	3.56e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—EGF—malignant glioma	6.43e-07	3.55e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—PIK3CB—malignant glioma	6.43e-07	3.55e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—TP53—malignant glioma	6.42e-07	3.55e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PTPN11—malignant glioma	6.39e-07	3.53e-06	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—AKT1—malignant glioma	6.33e-07	3.5e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CASP3—malignant glioma	6.32e-07	3.49e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IL2—malignant glioma	6.31e-07	3.49e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—MYC—malignant glioma	6.28e-07	3.47e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—STAT3—malignant glioma	6.22e-07	3.43e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—NCOR1—malignant glioma	6.2e-07	3.42e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—KRAS—malignant glioma	6.2e-07	3.42e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—FGF2—malignant glioma	6.19e-07	3.42e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CXCL8—malignant glioma	6.18e-07	3.41e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—PTEN—malignant glioma	6.15e-07	3.4e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—EGFR—malignant glioma	6.14e-07	3.39e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—EGFR—malignant glioma	6.12e-07	3.38e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—BRAF—malignant glioma	6.12e-07	3.38e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—KRAS—malignant glioma	6.11e-07	3.38e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PIK3CG—malignant glioma	6.1e-07	3.37e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—MYC—malignant glioma	6.09e-07	3.37e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—KRAS—malignant glioma	6.09e-07	3.37e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—PIK3CA—malignant glioma	6.06e-07	3.35e-06	CbGpPWpGaD
Crizotinib—TYK2—Disease—AKT1—malignant glioma	6.03e-07	3.33e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GSTT1—malignant glioma	6e-07	3.31e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MMP9—malignant glioma	5.97e-07	3.3e-06	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—AKT1—malignant glioma	5.97e-07	3.3e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—STAT3—malignant glioma	5.96e-07	3.29e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—EGFR—malignant glioma	5.96e-07	3.29e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—AKT2—malignant glioma	5.95e-07	3.29e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—PTEN—malignant glioma	5.94e-07	3.28e-06	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—AKT1—malignant glioma	5.93e-07	3.28e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CASP3—malignant glioma	5.91e-07	3.27e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IL2—malignant glioma	5.91e-07	3.26e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PPARG—malignant glioma	5.89e-07	3.25e-06	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—AKT1—malignant glioma	5.84e-07	3.23e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—KRAS—malignant glioma	5.8e-07	3.2e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MDM2—malignant glioma	5.79e-07	3.2e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—KRAS—malignant glioma	5.78e-07	3.19e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—MYC—malignant glioma	5.78e-07	3.19e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—RAF1—malignant glioma	5.77e-07	3.19e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PIK3CD—malignant glioma	5.72e-07	3.16e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—ERBB2—malignant glioma	5.71e-07	3.15e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—PIK3CA—malignant glioma	5.7e-07	3.15e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—EGFR—malignant glioma	5.65e-07	3.12e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—PIK3CB—malignant glioma	5.63e-07	3.11e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—KRAS—malignant glioma	5.63e-07	3.11e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PTGS1—malignant glioma	5.62e-07	3.1e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—PIK3CA—malignant glioma	5.62e-07	3.1e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—PIK3CA—malignant glioma	5.6e-07	3.09e-06	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—AKT1—malignant glioma	5.59e-07	3.09e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MMP9—malignant glioma	5.59e-07	3.09e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—PTEN—malignant glioma	5.56e-07	3.07e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—TP53—malignant glioma	5.51e-07	3.04e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—STAT3—malignant glioma	5.5e-07	3.04e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—FGF2—malignant glioma	5.48e-07	3.03e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—TP53—malignant glioma	5.43e-07	3e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—AKT1—malignant glioma	5.42e-07	3e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—AKT1—malignant glioma	5.42e-07	2.99e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—EGFR—malignant glioma	5.42e-07	2.99e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CXCL8—malignant glioma	5.41e-07	2.99e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PIK3CD—malignant glioma	5.36e-07	2.96e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—VEGFA—malignant glioma	5.36e-07	2.96e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—KRAS—malignant glioma	5.34e-07	2.95e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—PIK3CA—malignant glioma	5.33e-07	2.94e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—PIK3CA—malignant glioma	5.31e-07	2.93e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—STAT3—malignant glioma	5.31e-07	2.93e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—AKT1—malignant glioma	5.29e-07	2.92e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—AKT1—malignant glioma	5.27e-07	2.91e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—BCHE—malignant glioma	5.22e-07	2.89e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CASP3—malignant glioma	5.18e-07	2.86e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IL2—malignant glioma	5.17e-07	2.86e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—PIK3CA—malignant glioma	5.17e-07	2.86e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—SLC5A5—malignant glioma	5.16e-07	2.85e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TP53—malignant glioma	5.15e-07	2.85e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MDM2—malignant glioma	5.12e-07	2.83e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—KRAS—malignant glioma	5.12e-07	2.83e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—MYC—malignant glioma	5.11e-07	2.82e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—RAF1—malignant glioma	5.11e-07	2.82e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—CAV1—malignant glioma	5.05e-07	2.79e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—ERBB2—malignant glioma	5.05e-07	2.79e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—VEGFA—malignant glioma	5.02e-07	2.77e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—TP53—malignant glioma	5e-07	2.76e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—EGFR—malignant glioma	5e-07	2.76e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PIK3CB—malignant glioma	4.99e-07	2.75e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—STAT3—malignant glioma	4.97e-07	2.74e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—AKT1—malignant glioma	4.95e-07	2.74e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—MYC—malignant glioma	4.93e-07	2.73e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—PIK3CA—malignant glioma	4.9e-07	2.71e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MMP9—malignant glioma	4.9e-07	2.7e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—PTEN—malignant glioma	4.87e-07	2.69e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—EGFR—malignant glioma	4.83e-07	2.67e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CXCL8—malignant glioma	4.79e-07	2.65e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—KRAS—malignant glioma	4.72e-07	2.61e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—PIK3CA—malignant glioma	4.7e-07	2.6e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PIK3CB—malignant glioma	4.67e-07	2.58e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—AKT1—malignant glioma	4.65e-07	2.57e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PTGS2—malignant glioma	4.63e-07	2.56e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—MYC—malignant glioma	4.62e-07	2.55e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PIK3CG—malignant glioma	4.6e-07	2.54e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—AKT1—malignant glioma	4.59e-07	2.53e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CASP3—malignant glioma	4.59e-07	2.53e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IL2—malignant glioma	4.58e-07	2.53e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—AKT1—malignant glioma	4.57e-07	2.53e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—KRAS—malignant glioma	4.56e-07	2.52e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—EGFR—malignant glioma	4.52e-07	2.49e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PPARG—malignant glioma	4.44e-07	2.45e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—VEGFA—malignant glioma	4.4e-07	2.43e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—AKT1—malignant glioma	4.35e-07	2.4e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—STAT3—malignant glioma	4.35e-07	2.4e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—PIK3CA—malignant glioma	4.34e-07	2.4e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—AKT1—malignant glioma	4.34e-07	2.4e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MMP9—malignant glioma	4.33e-07	2.39e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PTEN—malignant glioma	4.31e-07	2.38e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—KRAS—malignant glioma	4.27e-07	2.36e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—AKT1—malignant glioma	4.23e-07	2.33e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—PIK3CA—malignant glioma	4.19e-07	2.31e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—GSTP1—malignant glioma	4.16e-07	2.3e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TP53—malignant glioma	4.05e-07	2.24e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PIK3CD—malignant glioma	4.05e-07	2.24e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CAT—malignant glioma	4.04e-07	2.23e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—MYC—malignant glioma	4.04e-07	2.23e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PTEN—malignant glioma	4.04e-07	2.23e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—AKT1—malignant glioma	4.01e-07	2.21e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—EGFR—malignant glioma	3.96e-07	2.19e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—PIK3CA—malignant glioma	3.92e-07	2.17e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—VEGFA—malignant glioma	3.89e-07	2.15e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—STAT3—malignant glioma	3.85e-07	2.13e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—AKT1—malignant glioma	3.84e-07	2.12e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—NCOR1—malignant glioma	3.82e-07	2.11e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TP53—malignant glioma	3.79e-07	2.09e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—KRAS—malignant glioma	3.74e-07	2.06e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—MYC—malignant glioma	3.58e-07	1.98e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—AKT1—malignant glioma	3.55e-07	1.96e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PIK3CB—malignant glioma	3.53e-07	1.95e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—EGFR—malignant glioma	3.5e-07	1.93e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PTGS2—malignant glioma	3.5e-07	1.93e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—PIK3CA—malignant glioma	3.43e-07	1.9e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—AKT1—malignant glioma	3.42e-07	1.89e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TP53—malignant glioma	3.32e-07	1.83e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—KRAS—malignant glioma	3.31e-07	1.83e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—AKT1—malignant glioma	3.2e-07	1.77e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CAV1—malignant glioma	3.11e-07	1.72e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PTEN—malignant glioma	3.05e-07	1.68e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PIK3CA—malignant glioma	3.04e-07	1.68e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TP53—malignant glioma	2.94e-07	1.62e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PIK3CA—malignant glioma	2.85e-07	1.57e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PIK3CG—malignant glioma	2.84e-07	1.57e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—AKT1—malignant glioma	2.8e-07	1.55e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PPARG—malignant glioma	2.74e-07	1.51e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PIK3CD—malignant glioma	2.49e-07	1.38e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—AKT1—malignant glioma	2.48e-07	1.37e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—AKT1—malignant glioma	2.33e-07	1.29e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PIK3CB—malignant glioma	2.17e-07	1.2e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PTGS2—malignant glioma	2.15e-07	1.19e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PIK3CA—malignant glioma	2.15e-07	1.19e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PTEN—malignant glioma	1.88e-07	1.04e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—AKT1—malignant glioma	1.76e-07	9.7e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PIK3CA—malignant glioma	1.32e-07	7.32e-07	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—AKT1—malignant glioma	1.08e-07	5.98e-07	CbGpPWpGaD
